Andere talen Femasys Inc.

Aandelen

FEMY

US31447E1055

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,29 ^USD	+4,45%		+1,57%	+32,31%

01/04	FEMASYS INC. : HC Wainwright handhaaft koopadvies	ZM
28/03	Femasys Inc. rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives	19/04
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives	18/04
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28/03
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update	28/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility	21/03
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape	21/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility	20/03
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	20/03
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024	13/03
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06/03
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	06/03
Femasys FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	29/02
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	28/02
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF	28/02
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer	06/02
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer	06/02
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial	26/01
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women	26/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Femasys Inc.

Aandelen

FEMY

US31447E1055

Andere talen

Filters